NL-OMON26365招募中不适用
Cumulative sum learning curves guiding multicenter multidisciplinary quality improvement of EUS-guided tissue acquisition of solid pancreatic lesions.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- QUEST
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •EUS-guided tissue acquisition of solid pancreatic lesion suspected for malignancy, patient >18 years old
排除标准
- •Patient <18 years old, no informed consent
研究者
相似试验
进行中（未招募）
1 期
A late stage clinical trial to investigate the efficacy and safety of SA237 in patients with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disordereuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD)MedDRA version: 16.1Level: PTClassification code 10029322Term: Neuromyelitis opticaSystem Organ Class: 10029205 - Nervous system disordersEUCTR2013-003752-21-ITChugai Pharmaceutical Co. Ltd70
进行中（未招募）
不适用
A late stage clinical trial to investigate the efficacy and safety of SA237 in patients with Neuromyelitis Optica and Neuromyelitis Optica Spectrum DisorderEUCTR2013-003752-21-ESChugai Pharmaceutical Co. Ltd70
进行中（未招募）
1 期
A late stage clinical trial to investigate the efficacy and safety of SA237 in patients with Neuromyelitis Optica and Neuromyelitis Optica Spectrum DisorderEUCTR2013-003752-21-HUChugai Pharmaceutical Co. Ltd83
进行中（未招募）
1 期
A late stage clinical trial to investigate the efficacy and safety of Satralizumab (SA237) in patients with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disordereuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD)MedDRA version: 20.0Level: LLTClassification code 10029322Term: Neuromyelitis opticaSystem Organ Class: 100000004852EUCTR2013-003752-21-DEF. Hoffmann-La Roche Ltd.83
进行中（未招募）
1 期
A late stage clinical trial to investigate the efficacy and safety of Satralizumab (SA237) in patients with Neuromyelitis Optica and Neuromyelitis Optica Spectrum DisorderEUCTR2013-003752-21-PLF. Hoffmann-La Roche Ltd.83